IL-6 inhibitors have been found efficacious in the treatment of idiopathic multicentric Castleman’s disease (6), rheumatoid arthritis (7), juvenile idiopathic arthritis, adult-onset Still’s disease (8), Takayasu arteritis (9), giant cell arteritis (10), cytokine release syndrome associated with tumor-specific T cell infusion therapy (11), and coronavirus 2019 (COVID-19) (12). The gene discussed is IL6; the disease is rheumatoid arthritis.